Therapeutic Adherence in CVD remains a vital yet often overlooked factor for better patient outcomes. Cardiovascular diseases account for 37% of deaths in Europe, placing a heavy burden on systems and economies. Non-adherence to prescribed treatments worsens this issue, leading to preventable deaths and higher costs. A recent guest blog by EFPIA examines the barriers, solutions, and policy needs to improve adherence (linked below).

Understanding the Adherence Challenge

CVD poses a significant threat across Europe, with non-adherence impacting half of all patients. Many fail to achieve control over their condition. Indeed, 31% never fill prescriptions, and 50% stray from advised regimens. Consequently, this leads to 200,000 avoidable deaths yearly. Moreover, the economic toll reaches €125 billion annually in preventable hospitalisations.

Several factors hinder adherence in CVD management. First, complex prescription processes create obstacles within healthcare systems. Next, intricate treatment plans and side effects deter consistent use. Furthermore, patient issues like low health literacy or forgetfulness play a role. Finally, socio-economic challenges, including medication costs and limited support, worsen the situation.

Innovative Solutions for Improvement

Fortunately, stakeholders are tackling these barriers with creative approaches. For instance, single-pill combinations simplify dosing for patients. Digital tools, such as mobile reminders and telemonitoring, offer real-time support. Also, patient education programmes enhance understanding of treatments. On top of that, training for healthcare professionals improves communication and trust. These efforts aim to boost therapeutic adherence in CVD significantly.

Prioritising adherence yields clear benefits for health systems. Fewer strokes and heart attacks will reduce the strain on available resources. Also, redefining unmet medical needs to include adherence will help unlocking additional research and funding to target this pressing issue. Ultimately, a broader focus on therapeutic adherence in CVD could save lives and cut costs.

Recommendations for Action

• Redefine unmet needs to prioritise adherence in policy frameworks.
• Fund innovations like single-pill combinations and digital tools.
• Strengthen collaboration among patients, professionals, and industry.
• Track adherence as a key performance metric in systems.

These steps can drive meaningful progress in CVD care.

Conclusion

Improving adherence in CVD treatment offers a path to better health and efficiency. With 200,000 lives lost yearly to non-adherence, the urgency is clear. Through innovation and policy shifts, stakeholders can make a difference. Read the EFPIA guest blog and how to transform outcomes for millions across Europe.

Table of Contents